What happened in autumn 2026?
On 30 October, US HHS announced a draft policy on preparation of products containing selected peptides, including BPC-157 acetate. It concerns how specified compounded preparations are handled; comments were still being collected when this text was checked. [51] [52]
This does not mean the FDA approved BPC-157 as a medicine for injuries. The announcement itself explains that compounded preparations do not undergo that approval. News from the USA also does not establish a product's availability or status in Poland. [51]
What did the two-person pilot study add?
A 2025 paper described brief follow-up of two adults. They reported no adverse effects, and selected blood tests showed no changes indicating damage to the organs assessed. Both had previously received BPC-157. [49]
This is very early information about tolerability under specific conditions. The study did not assess injury healing. It also cannot establish what happens in a larger group, after months of use or in people with other illnesses. [49]
Why can we still not call this an established treatment?
FDA materials from 2026 describe insufficient data to assess effectiveness and safety. Early reports are too small, brief or poorly described to answer patients' main questions. [50]
Well-designed studies of a specific injury would be needed, with an appropriate comparison group, assessment of pain and function, and monitoring of health problems. For example: does the person really return to work or sport sooner, and does the improvement last after follow-up ends?
How should you use this information?
Keep news about regulations separate from treatment results. Also check whether a publication concerns BPC-157 alone or a combination of substances. For this article, we used the pilot-study abstract and selected sections of the FDA assessment, not the full documentation of every study.
Go to the BPC-157 profile — it explains how it works, the knee pain findings, safety and anti-doping rules.
Where does this information come from?
Show sources and how they were checked
- HHS: announcement of a draft policy on peptide compounding
Federal Register, US · 30 October 2026 · full announcement; a draft, not drug approval. Accessed: 2 November 2026.
- HHS: draft policy and appendices concerning peptides
US document · October 2026 · policy and sections concerning the substances discussed. Accessed: 2 November 2026.
- Lee and Burgess: BPC-157 safety pilot in two people
Small pilot study · 2025 · abstract read. Accessed: 02.11.2026.
- FDA: ocena BPC-157 dla komisji doradczej
US regulator · assessment dated 11 May 2026, meeting in July 2026 · selected sections on research, safety and status. Accessed: 2 November 2026.